Application of New Cholesterol Guidelines to the Korean Adult Diabetic Patients
Bu Kyung Kim1, Hyeon Chang Kim2, Kyoung Hwa Ha3
1Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
Insights
New guidelines significantly expand statin therapy eligibility for Korean diabetic patients. The study highlights a critical gap in current dyslipidemia treatment, urging for guideline development and improved patient care.
Area of Science:
- Cardiology
- Endocrinology
- Public Health
Background:
- The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines broadened indications for statin therapy for hypercholesterolemia.
- Current statin therapy use among diabetic patients in Korea for dyslipidemia is suboptimal.
Purpose of the Study:
- To estimate the number of diabetic patients indicated for statin therapy in Korea using both the Third Adult Treatment Panel (ATP-III) and new ACC/AHA guidelines.
- To compare the eligibility for statin therapy between the two guideline sets in the Korean diabetic population.
Main Methods:
- Analysis of data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012.
- Inclusion of diabetic patients aged 30 years and older.
- Application of ATP-III and ACC/AHA guidelines to assess statin therapy indications.
Main Results:
- Among 1,598 diabetic patients not on dyslipidemia medication, 65.6% met ATP-III criteria, while 94.3% met the new ACC/AHA criteria.
- Overall, the new guidelines increased the proportion of eligible diabetic patients for statin therapy from 53.1% to 76.2% compared to ATP-III.
- Only 19.1% of the total 1,975 diabetic patients were on dyslipidemia medication.
Conclusions:
- The new ACC/AHA guidelines substantially increase the number of diabetic patients indicated for statin therapy in Korea.
- A significant gap exists between current statin therapy indications and actual treatment in Korean diabetic patients.
- Development of specific Korean guidelines and enhanced efforts are needed to ensure appropriate statin therapy for diabetic patients.
Abstract:
The American College of Cardiology and the American Heart Association (ACC/AHA) 2013 joint guidelines for the treatment of hypercholesterolemia expand the indications for statin therapy. This study was performed to estimate the numbers of diabetic patients indicated for statin therapy according to the Third Adult Treatment Panel (ATP-III) of the National Cholesterol Education Program guidelines and the new ACC/AHA guidelines in Korea. We analyzed the data from the Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012. Patients with diabetes over 30 yr of age were analyzed by the two guidelines. Of the total 1,975 diabetic patients, only 377 (19.1%) were receiving drugs for dyslipidemia. Among 1,598 patients who had not taken any medications for dyslipidemia, 65.6% would be indicated for statin therapy according to the ATP-III guidelines. When we apply the new guidelines, 94.3% would be eligible for statin therapy. Among the total diabetic patients, the new guidelines, compared with the ATP-III guidelines, increase the number eligible for statin therapy from 53.1% to 76.2%. The new guidelines would increase the indication for statin therapy for most diabetic patients. At present, many diabetic patients do not receive appropriate statin therapy. Therefore efforts should be made to develop the Korean guidelines and to ensure that more diabetic patients receive appropriate statin therapy.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Angina IV: Management
Drug Dosing: Obese Patients

